Control BRD to Help Protect Profits

July 21, 2010 — Maximizing pounds of gain and carcass value is just as important in upbeat cattle markets as it is during down times — and controlling bovine respiratory disease (BRD) helps ensure beef producers can keep everything they’ve earned.

“When cattle are healthy, they perform better.” says Daniel Scruggs, DVM, Pfizer Animal Health Veterinary Operations. “When cattle get sick, they’re not going to perform to their potential. Feed and input costs are not cheap, so why put them into cattle that are not going to convert efficiently?”

Many producers focus on the death loss attributed to BRD, but treatment rates of 40 percent to 50 percent or higher can be expensive when considering labor, treatment cost and reduced weight gain. Lower carcass weights and reduced quality grade are two ways BRD can steal from producers’ pocketbooks.1 Studies have shown that cattle with lung lesions had lower average daily gain (ADG), carcass weights and marbling scores than steers without lesions.2

“Performance and premiums are important in any market,” Dr. Scruggs says. “Whether you sell on a grid or on live weight, managing the impact BRD has on your check is important. The risk of BRD is always going to be there.”

To help manage that risk, researchers have shown that cattle treated with EXCEDE® (ceftiofur crystalline free acid) Sterile Suspension on arrival remain healthier and gain better.3,4

“EXCEDE has proven itself time and again as an effective means to manage BRD risk, either on arrival or for treatment,” Dr. Scruggs says. “The seven-day therapeutic benefit of EXCEDE has been proven in clinical studies, and provides solutions to manage sick cattle that shorter acting antimicrobials cannot provide. Less trips through the chute is worth a lot.”

Important Safety Information: EXCEDE should not be used in animals with known allergy to ceftiofur, penicillins and other cephalosporins (β-lactam group of antimicrobials). Though safe in cattle when properly administered, inadvertent injection in an artery is possible and fatal. EXCEDE has a pre-slaughter withdrawal time of 13 days in cattle. Do not use in calves to be processed for veal. For complete details, refer to the full prescribing information.

For more information, contact: 
Michelle Tollefson  
Pfizer Animal Health  
(212) 733-0502 

Jennifer Ryan
Bader Rutter
(970) 689-3385

1 Brooks KR, Raper KC, Ward CE, Holland CR, Step DL. Economic effects of bovine respiratory disease on feedlot cattle during backgrounding and finishing phases. P-1027 Oklahoma Agricultural Experiment Station Division of Agricultural Sciences and Natural Resources, Oklahoma University. Available at:¬1027%20Economic%20Effect%20of%20BRD1.pdf. Accessed May 17, 2010. 2 Gardner BA, Dolezal HG, Bryant LK, Owens FN, Smith RA. Health of finishing steers: Effects on performance, carcass traits and meat tenderness. J Anim Sc. 1999;77:3168-3175. 3 Pfizer Animal Health Technical Bulletin. Outcomes of 3-, 5-, or 7-day post-treatment intervals after a single administration of EXCEDE®. July 2004. 4 Pfizer Animal Health Technical Bulletin.  Bovine respiratory disease (BRD) morbidity, feed intake and weight gain in feedlot receiving systems after administration of EXCEDE at arrival. June 2007.

All brands are the property of their respective owners. ©2010 Pfizer Inc. All rights reserved. EXD10006



Mon–Fri, 8:30am–6:30pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.